Moderna (MRNA) Assets Average (2019 - 2026)

Moderna (MRNA) has 8 years of Assets Average data on file, last reported at $11.9 billion in Q1 2026.

• Assets Average for Q1 2026 came in at $11.9 billion, down 11.25% year-over-year; the trailing twelve-month figure through Mar 2026 was $11.9 billion (down 11.25% YoY), and the FY2025 annual result was $13.2 billion, down 18.69% from the prior year.
• Assets Average fell to $11.9 billion in Q1 2026 per MRNA's latest filing, from $12.2 billion in the prior quarter.
• Over five years, Assets Average peaked at $26.8 billion in Q2 2022 and troughed at $11.9 billion in Q1 2026.
• A 5-year average of $18.8 billion and a median of $17.6 billion in 2024 frame the typical range for Assets Average.
• The sharpest annual moves came in 2022 and 2024: Assets Average jumped 160.99% in 2022, then slipped 29.67% in 2024.
• A 5-year view of Assets Average shows it stood at $26.0 billion in 2022, then decreased by 27.04% to $18.9 billion in 2023, then declined by 20.94% to $15.0 billion in 2024, then slipped by 18.27% to $12.2 billion in 2025, then retreated by 2.64% to $11.9 billion in 2026.
• Business Quant data shows MRNA's Assets Average at $11.9 billion in Q1 2026, $12.2 billion in Q4 2025, and $12.1 billion in Q3 2025.